CC-5013
CC-5013 Brand names, CC-5013 Analogs
CC-5013 Brand Names Mixture
- No information avaliable
CC-5013 Chemical_Formula
C15H12N2O2
CC-5013 RX_link
http://www.rxlist.com/cgi/generic3/oxcarbazepine.htm
CC-5013 fda sheet
CC-5013 msds (material safety sheet)
CC-5013 Synthesis Reference
No information avaliable
CC-5013 Molecular Weight
252.268 g/mol
CC-5013 Melting Point
215.5 oC
CC-5013 H2O Solubility
308 mg/L at 25 oC (SRC PhysProp estimated -- MEYLAN,WM et al. (1996))
CC-5013 State
Solid
CC-5013 LogP
1.807
CC-5013 Dosage Forms
Suspension; Tablet (150 mg, 300 mg and 600 mg film coated)
CC-5013 Indication
For use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizures in children ages 4-16 with epilepsy.
CC-5013 Pharmacology
Oxcarbazepine is structurally a derivative of carbamazepine, adding an extra oxygen atom to the benzylcarboxamide group. This difference helps reduce the impact on the liver of metabolizing the drug, and also prevents the serious forms of anemia occasionally associated with carbamazepine. Aside from this reduction in side effects, it is thought to have the same mechanism as carbamazepine - sodium channel inhibition - and is generally used to treat the same conditions.
CC-5013 Absorption
Completely absorbed following oral administration. Food has no effect on the rate and extent of absorption of oxcarbazepine.
CC-5013 side effects and Toxicity
Isolated cases of overdose with oxcarbazepine have been reported. The maximum dose taken was approximately 24,000 mg. All patients recovered with symptomatic treatment.
CC-5013 Patient Information
CC-5013 Organisms Affected
Humans and other mammals
